Sanofi, tolebrutinib
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
Sanofi’s Tolebrutinib Delays MS Progression in Phase III Study Following Earlier Flops
The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of back-to-back failures in which tolebrutinib was unable to improve relapse rates in patients with relapsing MS.
Sanofi's tolebrutinib cuts MS progression by 31% in trial
Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was able to delay the time to six-month disability progression by 31% compared to placebo in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS).
Sanofi says tolebrutinib drug delayed progressive MS by 31%
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows
Sanofi SA (NASDAQ:SNY) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive multiple sclerosis (nrSPMS). The data demonstrated that tolebrutinib delayed the time to onset of 6-month confirmed disability progression (CDP) by 31% compared to placebo (HR 0.
Sanofi’s eyes approval after MS therapy slows disease progression by 31%
After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS patients.
Cleveland Clinic researcher advises Sanofi on multiple sclerosis drug that slows disease’s progression
Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing secondary progressive MS, according to data from a late stage trial presented Friday, Sept. 20, at a research congress in Copenhagen. The results confirm topline findings published on Sept. 2.
Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression
Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.
FierceBiotech21h
Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings
Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...
BioWorld18d
Sanofi BTK inhibitor tolebrutinib hits phase III endpoints in MS
Sanofi SA’s brain-penetrant Bruton's tyrosine kinase (BTK) inhibitor, tolebrutinib, met the primary endpoint in the phase III Hercules trial in non-relapsing secondary progressive multiple sclerosis ...
MarketWatch19d
Sanofi: Tolebrutinib Meets Primary Endpoint in Phase 3 Study
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
BioPharma Dive4h
Novo sinks on obesity drug results; Sanofi reveals anticipated MS data
A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.